PEPTIDE GUIDE

What Is AOD-9604?

AOD-9604 is a synthetic peptide derived from a short region at the end of human growth hormone. It was developed as a possible obesity medicine intended to influence fat metabolism without reproducing the full growth-related actions of growth hormone.

Animal experiments were encouraging, and a smaller human trial reported a weight-loss signal at one study level. A larger follow-up programme did not confirm a clinically useful benefit, and commercial obesity development was stopped in 2007.

Research statusUnapproved growth-hormone fragment with unsuccessful obesity development
Peptide typeModified growth-hormone 176-191 fragment
Clinical programmeObesity development did not establish efficacy
ApprovalNot an approved medicine
Last reviewedSeptember 2026
THE SHORT ANSWER

AOD-9604 is a modified 16-amino-acid fragment based on positions 176 to 191 of human growth hormone, with an additional tyrosine at the beginning of the chain. Mouse and rat studies reported changes in fat breakdown, fat oxidation and weight gain. The human obesity programme did not reproduce a dependable dose-related benefit, and the developer concluded that the Phase 2b results did not support commercial development. AOD-9604 is not an approved weight-loss medicine. The US Food and Drug Administration, normally shortened to FDA, says that human safety information is limited and notes serious adverse-event reports for which causation is unclear.

Is AOD-9604 growth hormone?

No. Human growth hormone is a 191-amino-acid protein made by the pituitary gland, a small hormone-producing organ beneath the brain. AOD-9604 contains a modified version of only the C-terminal region, meaning the section at the end of that protein.

The fragment was selected because earlier laboratory work suggested that some metabolic actions of growth hormone might be separated from its effects on body growth and insulin-like growth factor 1, normally shortened to IGF-1.

AOD-9604 is therefore related to growth hormone by sequence, but it is not a replacement growth hormone and is not an approved treatment for growth hormone deficiency.

What is AOD-9604 made from?

AOD-9604 is commonly described as a modified form of human growth hormone residues 176 to 191. A residue is an amino acid after it has been joined into a peptide chain. The sequence includes an additional tyrosine at its beginning.

It is not extracted from the human pituitary gland. It is manufactured from amino-acid building blocks under chemical synthesis conditions. The intended structure must then be separated from incomplete sequences and other reaction products.

Names such as “hGH fragment 176-191” are sometimes used loosely. AOD-9604's added amino acid and defined chemistry mean that evidence should refer to the actual material tested rather than to an approximate commercial label.

When was AOD-9604 first documented?

Research into metabolic fragments of growth hormone began before AOD-9604 itself was developed. Scientists were investigating whether regions near the end of the growth hormone chain could affect fat cells without activating the full growth hormone receptor programme.

Metabolic Pharmaceuticals Limited, an Australian biotechnology company, developed AOD-9604 during the 1990s. Preclinical papers appeared around 2000 and 2001. The name originally reflected “anti-obesity drug” and the company's compound number.

Human development advanced through several early and Phase 2 studies. A Phase 2b programme known as OPTIONS was intended to provide a stronger test of weight loss. In 2007, the company reported that the results did not support commercial viability as an obesity treatment.

PeriodDevelopment
1980s to 1990sResearchers examined metabolic regions of human growth hormone
Late 1990sMetabolic Pharmaceuticals developed AOD-9604
2000 to 2001Animal metabolism and weight-control papers were published
Early 2000sHuman safety and obesity studies were conducted
2007The developer stopped the obesity programme after unsuccessful Phase 2b results
2024 to 2026FDA compounding reviews highlighted limited safety evidence and manufacturing concerns

How is AOD-9604 synthesised and manufactured?

AOD-9604 can be made by solid-phase peptide synthesis. The process anchors the first protected amino acid to resin beads and then adds the remaining protected building blocks in sequence. Coupling chemicals create each peptide bond.

After assembly, the peptide is released from the resin and temporary protecting groups are removed. Preparative high-performance liquid chromatography separates the intended peptide from truncated chains, deletion sequences and chemical by-products. Mass spectrometry can confirm molecular mass, while analytical chromatography estimates purity.

Pharmaceutical manufacture would also require validated control of identity, peptide content, counter-ions, residual solvents, water, microbial contamination, bacterial endotoxin and stability. These controls are especially important for sterile products.

The FDA has pointed to peptide-related impurities and active pharmaceutical ingredient characterisation as specific concerns. An active pharmaceutical ingredient is the substance intended to produce the biological effect.

How was AOD-9604 expected to affect fat metabolism?

Early animal research reported increased lipolysis, which means release of stored fat from fat cells, and increased fat oxidation, meaning the use of fatty acids as fuel. It also reported less weight gain in animals fed diets designed to produce obesity.

In laboratory studies, AOD-9604 did not behave like full-length growth hormone at the growth hormone receptor and did not produce the same rise in blood glucose or reduction in insulin secretion seen in those experimental comparisons.

That was an attractive development idea: preserve a proposed effect on fat while avoiding growth and glucose-related actions. A mechanism can be selective in a cell or animal experiment without producing meaningful weight loss in people. Human trials are required to test that step.

What did the animal studies find?

Studies in genetically obese rats and diet-induced obese mice reported less weight gain and changes in biochemical measures of fat use. Some experiments used oral exposure, while others used injections into the abdominal cavity of animals.

Animal weight models are valuable for identifying possible metabolic pathways. They are not small human obesity trials. Rodents differ in energy expenditure, feeding, drug metabolism and growth hormone biology. A reduction in weight gain in a growing animal is also not the same as sustained weight reduction in an adult with obesity.

The animal work established a reason to conduct human studies. It could not establish a human treatment.

What happened in the human obesity programme?

The clinical programme included early safety work and multiple obesity studies. Public descriptions indicate that one 12-week Phase 2 study reported greater average weight loss at one tested level than with placebo. Placebo means a matching comparison without the active peptide.

The pattern was not consistently dose-related. A dose-related result normally becomes larger or more reliable as the tested exposure increases within a suitable range. When only one group appears positive among several comparisons, chance and study design become important explanations.

The larger OPTIONS Phase 2b trial was intended to test efficacy more convincingly. It failed to produce sufficient evidence of benefit, and the developer announced in 2007 that the results did not support commercial obesity development.

The negative programme result is more informative than repeating the most favourable number from a smaller study. Drug development depends on reproducible benefit across appropriate trials, not on one selected comparison.

What administration levels appeared in the studies?

The obesity programme tested multiple oral levels rather than establishing a therapeutic dose. Public and regulatory summaries describe daily study groups ranging across fractions of a milligram to several milligrams, with 1 milligram producing the most-discussed signal in an earlier trial.

The larger programme did not establish a dependable exposure-response relationship or an approved level. Route also matters. Results from an oral investigational tablet do not validate an injectable compounded product.

Study design, not dosing guidance

The levels, routes and durations in historical trials are included only to explain what researchers tested. They are not personal recommendations, and the unsuccessful programme did not produce an approved dosing schedule.

Does AOD-9604 cause weight loss in people?

The best answer is that clinical development did not establish it as an effective weight-loss medicine. A smaller study signal was not confirmed strongly enough in the larger programme to continue development.

This does not prove that the molecule has no biological activity. It means the evidence did not demonstrate a reliable balance of benefit and risk for obesity treatment.

Modern claims often present animal results or the favourable early comparison without the later programme outcome. A fair account must include both.

Does AOD-9604 affect blood sugar or IGF-1?

Animal experiments suggested that it did not activate the full growth hormone receptor pathway or reproduce several glucose-related effects of human growth hormone. Early human development also examined metabolic markers.

The absence of a signal in a limited study is not proof that every formulation, route or population is free from metabolic effects. People with diabetes, endocrine disorders or multiple medicines were not represented adequately enough to support general safety claims.

It is also incorrect to claim that AOD-9604 raises growth hormone or IGF-1 in the same way as a growth hormone-releasing peptide. Its development concept was different.

Has AOD-9604 been studied for cartilage or osteoarthritis?

Later laboratory and animal work has examined cartilage and joint biology. These studies are separate from the obesity programme and remain preclinical or early translational research.

A molecule can influence cartilage cells in a laboratory without improving pain, mobility or joint structure in people. Osteoarthritis trials need clinically meaningful outcomes, suitable imaging, control groups and adequate follow-up. That level of evidence has not established AOD-9604 as an approved joint treatment.

What are the known safety limits?

Historical development exposed people to defined oral research formulations and produced some short-term safety information. It did not establish the long-term safety of present-day compounded or online products, especially through different routes.

The FDA states that it has identified no or only limited safety-related information and cannot determine whether compounded AOD-9604 would cause harm. It also notes serious adverse events that may be associated with the substance, while making clear that causation is uncertain.

Peptide-specific risks include immune reactions, aggregation and impurities. Sterile-product risks include bacterial or fungal contamination and endotoxin. In 2021, a US compounder recalled injectable AOD-9604 because sterility assurance was lacking. No adverse events had been reported at the time, but a non-sterile injected product can cause life-threatening infection.

Is AOD-9604 approved?

No. AOD-9604 is not an FDA-approved medicine for obesity, fat loss, joint disease or any other indication.

Australia permits AOD-9604 in certain compounded circumstances under its own regulatory framework, but that does not make it a fully evaluated approved medicine for weight loss. Regulatory position depends on country and product.

The FDA discussed AOD-9604-related bulk substances through its compounding review process. A compounding category is not drug approval. Compounded drugs do not undergo the same premarket review for safety, effectiveness and quality as an approved medicine.

Is AOD-9604 prohibited in sport?

Growth hormone fragments and related factors can fall within World Anti-Doping Agency rules. Athletes should use the current Prohibited List and seek formal anti-doping advice rather than rely on a product's marketing category.

The absence of approval does not prevent a substance from being prohibited. “Research use” is not an anti-doping exemption.

What benefits are claimed, and what does the evidence support?

ClaimWhat the evidence supports
Produces substantial weight lossNot established; larger obesity development was unsuccessful
Targets fat without affecting growthSupported as a design aim and in some preclinical findings, not as an approved clinical benefit
Preserves muscle while reducing fatNo dependable controlled human evidence establishing this outcome
Improves cartilage or joint painLaboratory and animal research only; no approved osteoarthritis treatment
Has no growth-hormone-related risksToo broad; it is a different molecule, but human safety evidence remains limited
Is safe because early trials occurredEarly trials do not establish long-term safety of different routes and unregulated products

How should the obesity evidence be read?

AOD-9604 passed through several evidence stages. The early biological idea was that the end portion of growth hormone might influence fat metabolism without causing the full hormone's growth-related effects. Rodent studies then reported lower weight gain or altered fat metabolism in selected models.

The programme moved into people because animal results cannot answer whether a treatment works clinically. Early human studies explored safety, pharmacokinetics and possible weight signals. The larger Phase 2b trial was the important test of whether the earlier promise translated into a useful effect.

Phase 2b is a mid-stage trial intended to provide a clearer estimate of efficacy and select an exposure for later development. The developer reported that the results did not support continuing commercial obesity development. That outcome carries more weight than isolated early signals because it came from the stage designed to test the clinical hypothesis more directly.

An unsuccessful programme is still valuable evidence. It prevents cell and animal findings from being presented as though human weight loss had never been tested.

What was the difference between oral and injected research?

Peptides are often broken down in the digestive system. AOD-9604 attracted interest partly because animal studies reported activity after oral administration under selected conditions. Researchers also examined other formulations during development.

Oral bioavailability is the proportion of a swallowed amount that reaches the circulation in an active form. A biological effect after oral administration in a rodent does not establish dependable oral absorption in people. Some effects could also involve local digestive pathways or metabolites.

Results from one route cannot be transferred to another. An oral capsule, under-the-tongue product and subcutaneous injection produce different exposure. Subcutaneous means into the fatty tissue beneath the skin.

Product sellers sometimes combine results from every route while avoiding the failed clinical endpoint. That gives an inaccurate account of the programme.

What is known about breakdown and metabolites?

AOD-9604 is based on amino acids 177 to 191 at the end of human growth hormone, with an additional tyrosine at the beginning. Proteases can cut it into shorter fragments. A protease is an enzyme that breaks peptide bonds.

Animal metabolism studies examined the parent peptide and breakdown products. Identifying a metabolite does not show that it produces a beneficial effect in people. Researchers need to measure how much is formed, how long it remains and which receptors or pathways it affects.

Claims that the molecule works by one exact “fat-burning pathway” are stronger than the evidence. Fat release, oxidation and long-term loss of body fat are related but different outcomes. Lipolysis releases fatty acids from stored fat. Oxidation uses those fatty acids for energy. Released fat can be stored again if energy balance does not change.

Why does failure to raise IGF-1 not prove complete safety?

Avoiding a sustained rise in insulin-like growth factor-1 was part of the development rationale. IGF-1 mediates many growth-hormone effects, and excessive growth-hormone signalling can affect glucose, fluid balance and tissue growth.

A limited study finding no meaningful IGF-1 rise addresses one measurement under those conditions. It does not test every tissue, exposure, duration or impurity. It also does not address risks unrelated to IGF-1.

Safety conclusions require adequate participant numbers, defined adverse-event collection and follow-up. A failed efficacy programme may end before rare or long-term harms are fully characterised.

What is the cartilage research context?

Growth hormone and related fragments have been investigated in cartilage-cell and osteoarthritis models. Cartilage is the smooth connective tissue covering the ends of bones in a joint. Osteoarthritis involves cartilage damage, changes in bone and inflammation across the whole joint.

An effect on cultured chondrocytes, the cells found in cartilage, does not show that a compound relieves pain or preserves a human joint. Laboratory concentrations expose cells directly, while an administered peptide must reach the joint in an active form.

Human osteoarthritis evidence would need validated pain and function outcomes, imaging interpreted cautiously and adequate comparison with exercise, weight management and established treatments. That programme has not established AOD-9604 as an osteoarthritis medicine.

What did the 2021 recall show?

In 2021, the FDA announced a voluntary recall of sterile compounded products made by Innoveix Pharmaceuticals, including products containing AOD-9604. The recall concerned a lack of assurance of sterility.

A sterility recall does not prove that AOD-9604 itself caused an adverse effect. It demonstrates a separate product-level risk. Injected material bypasses many of the body's surface defences, so microbial contamination can cause serious infection.

Chemical purity and sterility are different. A batch can have the expected peptide peak and still fail microbial or endotoxin requirements.

What would be required to restart clinical development?

A new programme would need to justify why a different formulation, route, population or endpoint could succeed where the obesity programme did not. That justification should come from new evidence, not simply a reinterpretation of old animal results.

Researchers would need a reproducible product, updated toxicology and early human pharmacokinetic work. A controlled efficacy trial should measure clinically meaningful weight and body-composition changes, account for diet and activity, and follow participants after treatment stops.

The programme would also need to report results whether positive or negative. Trial registration and publication reduce the risk that only favourable findings become visible.

What does “generally recognised as safe” mean in this context?

AOD-9604 has sometimes been discussed in connection with the US food-ingredient concept “generally recognised as safe”, shortened to GRAS. GRAS concerns a substance's intended use in food under specified conditions. It is not FDA approval of a medicine and does not establish that injecting the substance is safe.

Route and purpose matter. Evidence used for limited food exposure cannot be transferred to a sterile injectable product, repeated systemic exposure or treatment of obesity. A food-status argument also cannot replace evidence of effectiveness.

Readers should therefore ask which form, route, amount and intended use a regulatory statement actually covers.

How does AOD-9604 differ from approved metabolic medicines?

Semaglutide and tirzepatide act through defined incretin-hormone receptors and have large human trial programmes. Their labels describe indications, contraindications, adverse reactions and manufacturing controls.

AOD-9604 was developed through a different mechanism and its obesity programme did not establish efficacy. It should not be described as a peptide alternative to an approved medicine merely because all are associated with weight research.

Comparison also requires the same outcome and population. A short animal change in fat oxidation cannot be set beside a year-long percentage change in human body weight.

What questions should be asked of a commercial claim?

The first question is whether the claim refers to AOD-9604 itself, another growth-hormone fragment or full growth hormone. The second is whether the cited work involved cells, animals or people.

Readers should then check the route, formulation, comparison group and outcome. If a page mentions “clinical trials” without reporting that the Phase 2b obesity programme failed to support development, it leaves out the most important efficacy result.

FREQUENTLY ASKED QUESTIONS

Frequently asked questions

Is AOD-9604 a peptide?

Yes. It is a synthetic peptide based on a short region at the end of human growth hormone.

Is AOD-9604 human growth hormone?

No. It contains only a modified fragment and does not replace the complete 191-amino-acid hormone.

Does AOD-9604 cause weight loss?

Animal studies were positive, but the human development programme did not establish it as an effective weight-loss medicine.

Why did AOD-9604 development stop?

The developer reported that the larger Phase 2b results did not support commercial development for obesity.

Is AOD-9604 FDA approved?

No. It has no FDA-approved indication.

Is AOD-9604 a GLP-1 medicine?

No. It is not a glucagon-like peptide-1 receptor agonist and should not be compared with semaglutide or tirzepatide as though the mechanisms and evidence were equivalent.

Does AOD-9604 raise IGF-1?

Its design aimed to avoid the full growth hormone and IGF-1 pathway. Limited findings do not justify a guarantee that every use or formulation has no endocrine effects.

How is AOD-9604 made?

It is assembled from protected amino-acid building blocks, purified and tested using analytical methods.

Has AOD-9604 been tested by injection for weight loss?

The main obesity programme used defined investigational formulations and did not establish an approved injectable treatment. Results cannot be transferred between routes.

Are there established safe administration levels?

No approved level exists. Historical research levels are study-design facts, not personal guidance.

What the evidence supports today

AOD-9604 is a useful example of why preclinical promise is not enough. The molecule was designed around a plausible metabolic idea and produced positive animal findings. It progressed into human research, where the larger programme did not demonstrate sufficient efficacy.

The scientifically responsible conclusion is not that it is a proven “fat-burning peptide”. It is an unapproved growth-hormone fragment whose obesity development failed and whose present compounded-product safety is incompletely characterised.

Future research would need a clearly defined product, a justified route, adequate controlled trials, meaningful body-composition outcomes and longer safety follow-up.

RESEARCH AND MEDICAL NOTICE

This guide explains research and regulatory evidence. It does not recommend AOD-9604 or provide weight-loss, dosing, administration, cycling, stacking or purchasing advice.

Research reviewed through September 2026.